Olmesartan medoxomil/azelnidipine
Alternative Names: Azelnidipine/olmesartan medoxomil; CS-866AZ; RezaltasLatest Information Update: 05 Nov 2023
At a glance
- Originator Daiichi Sankyo Company
- Class Antihypertensives; Dihydropyridines; Imidazoles; Imino acids; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 16 Apr 2010 Launched for Hypertension in Japan (PO)
- 21 Jan 2010 Registered for Hypertension in Japan (PO)
- 11 Dec 2008 Preregistration for Hypertension in Japan (PO)